About: Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
Creator	Shu, Chih-Wen Chang, Hong-Tai Hsiao, Michael Hsieh, Chiao-Wei Kuo, Soong-Yu Lee, Cheng-Hsin Li, Ju-Yueh Liu, Li-Feng Liu, Pei-Feng Wu, Chih-Hsuan Bhatnagar, Sanchita Tzeng, Yen-Dun Fang, Minggang Hsieh, Kuo S-Y Huan, Chongmin Li, J-Y Liu, L-F Liu, P-F Tzeng, Y-Dt
Source	PMC
abstract	Background: Chemotherapy is the main treatment for triple-negative breast cancer (TNBC), which lack molecular markers for diagnosis and therapy. Cancer cells activate chemoresistant pathways and lead to therapeutic failure for patients with TNBC. Several kinases have been identified as chemoresistant genes. However, the involvement of kinases in the chemoresistance in TNBC cells is not fully understood. Methods: We employed a kinome siRNA library to screen whether targeting any kinases could increase the chemosensitivity of TNBC cell lines. The effects of kinase on cell viability in various breast cancer cells were validated with ATP level and colony formation. Protein expression and phosphorylation were determined by immunoblotting. The Cancer Genome Atlas (TCGA) dataset was collected to analyze the correlation of Src expression with prognosis of TNBC patients. Results: Primary screening and validation for the initial hits showed that Src kinase was a potential doxorubicin-resistant kinase in the TNBC cell lines MDA-MB-231 and Hs578T. Both siRNA against Src and the Src inhibitor dasatinib enhanced the cytotoxic effects of doxorubicin in TNBC cells. Moreover, phosphorylation of AKT and signal transducer and activator of transcription 3 (STAT3), downstream effectors of Src, were accordingly decreased in Src-silenced or -inhibited TNBC cells. Additionally, TCGA data analysis indicated that Src expression levels in tumor tissues were higher than those in tumor-adjacent normal tissues in patients with TNBC. High co-expression level of Src and STAT3 was also significantly correlated with poor prognosis in patients. Conclusion: Our results showed that Src-STAT3 axis might be involved in chemoresistance of TNBC cells.
has issue date	2018-11-09(xsd:dateTime)
bibo:doi	10.3389/fphar.2018.01285
bibo:pmid	30473665
has license	cc-by
sha1sum (hex)	2890249daa0601affd680a8aadee19b50ed2044d
schema:url	https://doi.org/10.3389/fphar.2018.01285
resource representing a document's title	Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
has PubMed Central identifier	PMC6238227
has PubMed identifier	30473665
schema:publication	Front Pharmacol
resource representing a document's body	covid:2890249daa0601affd680a8aadee19b50ed2044d#body_text
is schema:about of	named entity 'Cancer cells' named entity 'cells' covid:arg/2890249daa0601affd680a8aadee19b50ed2044d named entity 'kinases' named entity 'molecular markers' named entity 'Breast Cancer' named entity 'Triple-Negative' named entity 'Src kinase' named entity 'chemoresistance' named entity 'phosphoinositide 3-kinases' named entity 'ERK pathway' named entity 'electrophoretically' named entity 'chemotherapy' named entity 'doxorubicin' named entity 'primary antibodies' named entity 'chemoresistance' named entity 'chemotherapeutic drugs' named entity 'correlation' named entity 'chemoresistance' named entity 'TRIzol' named entity 'TNBC' named entity 'TNBC' named entity 'gene knockdown' named entity 'Kaplan-Meier' named entity 'cell survival' named entity 'pharmacological' named entity 'anti-cancer drugs' named entity 'Protein kinases' named entity 'tyrosine' named entity 'cell lysates' named entity 'tumorigenesis' named entity 'mutation' named entity 'mRNA' named entity 'Src' named entity 'Src' named entity 'luciferase' named entity 'tumor' named entity 'L-glutamine' named entity 'serine' named entity 'AKT' named entity 'HER2' named entity 'shRNA' named entity 'chemotherapeutic drug' named entity 'streptomycin' named entity 'targeted therapy' named entity 'chemoresistance' named entity 'Rapamycin' named entity 'siRNA' named entity 'chemoresistance' named entity 'protein' named entity 'Cox proportional hazards models' named entity 'siRNA' named entity 'ROS1' named entity 'Src' named entity 'STAT3' named entity 'mRNA' named entity 'cancer stem cells' named entity 'cytotoxicity' named entity 'Src' named entity 'kinase domain' named entity 'dasatinib' named entity 'doxorubicin' named entity 'doxorubicin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software